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A BS TR AC T
background
Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically signifi-
cant activity in myelofibrosis.
methodS
In this double-blind trial, we randomly assigned patients with intermediate-2 or high-
risk myelofibrosis to twice-daily oral ruxolitinib (155 patients) or placebo (154 patients). 
The primary end point was the proportion of patients with a reduction in spleen vol-
ume of 35% or more at 24 weeks, assessed by means of magnetic resonance imaging. 
Secondary end points included the durability of response, changes in symptom bur-
den (assessed by the total symptom score), and overall survival.
resulTS
The primary end point was reached in 41.9% of patients in the ruxolitinib group as 
compared with 0.7% in the placebo group (P<0.001). A reduction in spleen volume was 
maintained in patients who received ruxolitinib; 67.0% of the patients with a response 
had the response for 48 weeks or more. There was an improvement of 50% or more in 
the total symptom score at 24 weeks in 45.9% of patients who received ruxolitinib as 
compared with 5.3% of patients who received placebo (P<0.001). Thirteen deaths oc-
curred in the ruxolitinib group as compared with 24 deaths in the placebo group 
(hazard ratio, 0.50; 95% confidence interval, 0.25 to 0.98; P = 0.04). The rate of discon-
tinuation of the study drug because of adverse events was 11.0% in the ruxolitinib 
group and 10.6% in the placebo group. Among patients who received ruxolitinib, ane-
mia and thrombocytopenia were the most common adverse events, but they rarely led 
to discontinuation of the drug (in one patient for each event). Two patients had trans-
formation to acute myeloid leukemia; both were in the ruxolitinib group.
conclusionS
Ruxolitinib, as compared with placebo, provided significant clinical benefits in 
patients with myelofibrosis by reducing spleen size, ameliorating debilitating 
myelofibrosis-related symptoms, and improving overall survival. These benefits 
came at the cost of more frequent anemia and thrombocytopenia in the early part 
of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, 
NCT00952289.)
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Myelofibrosis, a myeloproliferative neoplasm, is manifested by abnormal blood counts (anemia, thrombocytosis 
or thrombocytopenia, and leukocytosis or leuko-
penia), splenomegaly, and debilitating symptoms 
(e.g., fatigue, weakness, abdominal pain, cachexia, 
weight loss, pruritus, night sweats, and bone pain), 
which are thought to be caused by the combined 
effects of massive splenomegaly and elevated levels 
of proinflammatory cytokines.1 Survival ranges 
from approximately 2 to 11 years, depending on 
defined prognostic factors.2 Traditional therapeutic 
options, including splenectomy, have limited bene-
fit.3 Although allogeneic stem-cell transplantation 
may cure myelofibrosis, few patients are eligible for 
this treatment.
Although the gain-of-function mutation in the 
gene encoding Janus kinase (JAK) 2 (JAK2 V617F) 
is present in approximately 50% of patients with 
primary myelofibrosis, other mechanisms of direct 
or indirect activation of the intracellular JAK–
signal transducer and activator of transcription 
(STAT) pathway are known,4 suggesting that dys-
regulation of this pathway is a central pathogenic 
component in myelofibrosis, regardless of the mu-
tational status of JAK2. Also, proinflammatory 
cytokines that play an important role in myelo-
fibrosis signal through JAK 1 (JAK1) and JAK2.5 
In a phase 1–2 trial of ruxolitinib (INCB018424, 
Incyte), a potent inhibitor of JAK1 and JAK2,6,7 
patients with myelofibrosis had durable reductions 
in splenomegaly and improvements in myelofi-
brosis-related symptoms, regardless of their status 
with respect to the JAK2 V617F mutation. To fur-
ther evaluate the efficacy and safety of ruxoli-
tinib, we conducted the Controlled Myelofibro-
sis Study with Oral JAK Inhibitor Treatment I 
(COMFORT-I), a randomized, double-blind, pla-
cebo-controlled trial involving patients with inter-
mediate-2 or high-risk myelofibrosis.
Me thods
PATIENTS
Patients were eligible for the study if they were 
18 years of age or older and had primary myelo-
fibrosis, post–polycythemia vera myelofibrosis, or 
post–essential thrombocythemia myelofibrosis ac-
cording to 2008 World Health Organization crite-
ria,8 with a life expectancy of 6 months or longer, 
an International Prognostic Scoring System (IPSS) 
score2 (see Table S1 in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org) of 2 (intermediate-2 risk) or 3 or more 
(high risk), an Eastern Cooperative Oncology Group 
performance status9 of 3 or less (on a scale from 
0 to 5, with higher scores indicating greater dis-
ability; see the Supplementary Appendix for further 
details), less than 10% peripheral-blood blasts, 
an absolute peripheral-blood CD34+ cell count of 
more than 20×106 per liter, a platelet count of 
100×109 per liter or more, and palpable spleno-
megaly (≥5 cm below the left costal margin). Pa-
tients had disease that was refractory to available 
therapies, had side effects requiring their discon-
tinuation, or were not candidates for available ther-
apies and had disease requiring treatment. The trial 
protocol, which describes in detail the inclusion 
and exclusion criteria and other information about 
the trial design, as well as the statistical analysis 
plan, is available at NEJM.org.
Study Oversight
The protocol was approved by the institutional re-
view board at each participating site. The study was 
conducted in accordance with the International 
Conference on Harmonization guidelines for Good 
Clinical Practice. All patients provided written in-
formed consent.
Data were collected by the academic investi-
gators and analyzed by the sponsor of the study, 
Incyte. The sponsor, in collaboration with the aca-
demic investigators, interpreted the data. The first 
author and an author who was an employee of the 
sponsor wrote the initial draft of the manuscript, 
with assistance from a medical writer who was 
paid by the sponsor. All the authors contributed to 
subsequent drafts and made the decision to submit 
the article for publication. All the authors vouch for 
the accuracy and completeness of the reported data 
and for the fidelity of this report to the protocol.
STUDY DESIGN AND TREATMENT
This randomized, double-blind, placebo-controlled, 
phase 3 trial was conducted at 89 sites in the Unit-
ed States, Australia, and Canada. Patients were 
randomly assigned in a 1:1 ratio to receive oral 
ruxolitinib phosphate tablets or matched placebo. 
The starting dose of ruxolitinib depended on the 
baseline platelet count: 15 mg twice daily for a 
platelet count of 100×109 to 200×109 per liter and 
20 mg twice daily for a count that exceeded 
200×109 per liter. The dose was adjusted for lack of 
efficacy or excess toxicity as specified in the proto-
col (see the Supplementary Appendix). Unblinding 
of the study-drug assignments and crossover from 
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placebo to ruxolitinib were permitted for protocol-
defined worsening splenomegaly (see the Supple-
mentary Appendix). The prospectively defined cut-
off point for data analysis occurred when half the 
patients remaining in the study had completed the 
week 36 visit and when all the patients had com-
pleted the week 24 evaluation or discontinued treat-
ment. After crossover, data for patients who were 
initially assigned to placebo were not included in 
the analyses, except for the intention-to-treat analy-
sis of overall survival.
The primary end point was the proportion of 
patients with a reduction of 35% or more in spleen 
volume from baseline to week 24, measured by 
means of magnetic resonance imaging or com-
puted tomography. Secondary end points included 
the duration of the reduction in spleen volume; the 
proportion of patients with a reduction in the total 
symptom score of 50% or more from baseline to 
week 24, as assessed with the modified Myelofi-
brosis Symptom Assessment Form (MFSAF), ver-
sion 2.0 (see the Supplementary Appendix)10,11; 
the change in the total symptom score from base-
line to week 24; and overall survival. The analysis 
of overall survival was updated at the time of a 
planned data-collection cutoff 4 months after the 
primary analysis. Patients completed the MFSAF 
every night; this electronic diary was used to evalu-
ate symptoms of night sweats, itching, abdominal 
discomfort, pain under the ribs on the left side, a 
feeling of fullness (early satiety), muscle or bone 
pain, and inactivity. Scores ranged from 0 (“ab-
sent” symptoms) to 10 (“worst imaginable” symp-
toms), and the total symptom score was the sum 
of the individual scores, excluding inactivity. Ex-
ploratory end points included changes in body 
weight and the JAK2 V617F allele burden, achieve-
ment of independence from transfusions,12 and 
additional patient-reported outcomes (see the Sup-
plementary Appendix).
Statistical Analysis
The study was designed to enroll 240 patients, pro-
viding 97% power to detect a treatment difference 
in spleen-volume response at a two-sided alpha 
level of 0.05, assuming a response rate of 30% or 
more for ruxolitinib and a response rate of 10% or 
less for placebo. Analyses were conducted in accor-
dance with the intention-to-treat principle. For all 
applicable variables, however, patients with missing 
baseline values were excluded from the analyses of 
change and percent change from baseline. In the 
analyses of change from baseline to week 24, pa-
tients who discontinued the study drug or crossed 
over before week 24 were counted as not having a 
response (for response measures of a reduction in 
spleen volume and symptom improvement). Sec-
ondary efficacy variables were tested in a fixed-
sequence testing procedure at an alpha level of 
0.05. The durability of spleen response and sur-




From September 2009 through April 2010, a total 
of 309 patients were enrolled: 155 were random-
ly assigned to ruxolitinib, and 154 were randomly 
assigned to placebo. Baseline characteristics were 
similar in the two groups (Table 1). The median 
spleen volume was more than 2500 cm3 (>10 times 
the median normal spleen volume of 200 cm3).13-15 
A total of 38.2% of the patients had IPSS inter-
mediate-2–risk disease, and 61.2% had high-risk 
disease.
At the time of the prospectively defined data 
cutoff (median follow-up, 32 weeks), 134 patients 
in the ruxolitinib group (86.5%) and 78 in the pla-
cebo group (50.6%) were receiving the randomly 
assigned study drug. Thirty-six patients in the pla-
cebo group (23.4%) crossed over to ruxolitinib 




The proportion of patients with a reduction of 
35% or more in spleen volume at week 24 (primary 
end point) was 41.9% in the ruxolitinib group as 
compared with 0.7% in the placebo group (odds 
ratio, 134.4; 95% confidence interval [CI], 18.0 to 
1004.9; P<0.001) (Fig. 1A). Additional prespeci-
fied analyses showed that among the patients for 
whom baseline and week 24 data were available, 
the 139 patients receiving ruxolitinib had a mean 
reduction in spleen volume of 31.6% (median, 
33.0%) at week 24; the 106 patients receiving 
placebo had a mean increase of 8.1% (median, 
8.5%). Almost all patients receiving ruxolitinib had 
some degree of reduction in spleen volume (Fig. 
1B). The majority of patients receiving placebo 
had spleen growth. Changes in palpable spleen 
length in the ruxolitinib and placebo groups mir-
rored the changes in spleen volume. The reduc-
tion in spleen volume was durable with continued 
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therapy (Fig. 1C). For this secondary end point, 
among patients who had a reduction of 35% or 
more in spleen volume, 67.0% (95% CI, 46.4 to 
81.1) had a reduction in spleen volume that was 
maintained for 48 weeks or more (loss of response 
was defined as a reduction of <35% from base-
line and an increase of ≥25% from the nadir).
Symptoms and Other Patient-Reported Outcomes
The proportion of patients with a reduction of 50% 
or more in the total symptom score from baseline 
to week 24, a prespecified secondary end point, 
was significantly higher in the ruxolitinib group 
than in the placebo group (45.9% vs. 5.3%; odds 
ratio, 15.3; 95% CI, 6.9 to 33.7; P<0.001). Addi-
tional prespecified analyses showed that among 
the patients for whom baseline and week 24 data 
were available, the 129 patients receiving ruxoli-
tinib had a mean improvement of 46.1% (median, 
56.2%) in the total symptom score at week 24; 
the 103 patients receiving placebo had a mean 
worsening of 41.8% (median, 14.6%) in the score 
(P<0.001). The improvement was rapid and was 
maintained over the 24-week period during which 
symptom data were collected (Fig. 2A). Most pa-
tients who received ruxolitinib had improvement 
in symptoms; the majority of patients who received 
placebo had worsening of symptoms (Fig. 2B).
A post hoc analysis showed that patients who 
received ruxolitinib had improvement in each in-
dividual symptom assessed on the MFSAF (Fig. 
2C), whereas symptoms worsened in the placebo 
group (P<0.01 for all comparisons with placebo).
Prespecified analyses were conducted to cross-
validate the modified MFSAF, version 2.0. The 
Patient Global Impression of Change and other 
patient-reported outcomes mirrored changes in 
symptom scores (Fig. S3A, S3B, and S3C in the 
Supplementary Appendix). Patients who received 
ruxolitinib had weight gain, whereas those receiv-
ing placebo had weight loss (Fig. S4 in the Supple-
mentary Appendix). In the ruxolitinib group, 62.7% 
of patients with a reduction in spleen volume of 
35% or more had improvement of 50% or more in 
spleen-related symptoms (as indicated by the sum 
of MFSAF scores for abdominal discomfort, pain 
under the ribs on the left side, and a feeling of 
fullness [early satiety]); however, this level of im-
provement also occurred in 46.9% of patients with 
a reduction in spleen volume of less than 35%. An 
additional post hoc analysis showed an improve-
ment of 50% or more in nonabdominal symptoms 
(night sweats, bone or muscle pain, and pruritus) 
in 58.6% of patients with reductions in spleen 
volume of 35% or more and in 54.1% of patients 
with reductions in spleen volume of less than 35%.
Table 1. Baseline Characteristics of the Patients.*
Variable Ruxolitinib (N = 155) Placebo (N = 154)
Median age (range) — yr 66 (43–91) 70 (40–86)
Male sex — % of patients 51.0 57.1
Myelofibrosis subtype — % of patients
Primary myelofibrosis 45.2 54.5
Post–polycythemia vera myelofibrosis 32.3 30.5
Post–essential thrombocythemia myelofibrosis 22.6 14.3
IPSS risk status — % of patients
High 58.1 64.3
Intermediate 2 41.3 35.1
Previous hydroxyurea use — % of patients 67.1 56.5
Median platelet count (range) — ×10−9/liter 262 (81–984) 238 (100–887)
Median hemoglobin (range) — g/liter 105 (66–170) 105 (35–173)
Median palpable spleen length (range) — cm 16 (0–33)† 16 (5–34)
Median spleen volume (range) — cm3 2598 (478–7462) 2566 (521–8881)
JAK2 V617F–positive — % of patients 72.9 79.9
* There were no significant differences between the two groups with the exception of age (P<0.05). IPSS denotes 
International Prognostic Scoring System.
† One patient had a baseline spleen length recorded as nonpalpable in error but had a prior measurement of 16 cm and 
a baseline spleen volume of 2450 cm3.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 27, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Ruxolitinib for Myelofibrosis
n engl j med 366;9 nejm.org march 1, 2012 803
Subgroups
In a post hoc analysis of subgroups, mean changes 
in spleen volume among patients with the JAK2 
V617F mutation were −34.6% in the ruxolitinib 
group and 8.1% in the placebo group; the corre-
sponding changes among patients without the mu-
tation were −23.8% and 8.4% (P value for interac-
tion, 0.07). The changes in the total symptom score 
among patients with the JAK2 V617F mutation were 
−52.6% (improvement) in the ruxolitinib group and 
42.8% (worsening) in the placebo group, and the 
changes among those without the mutation were 
−28.1% and 37.2%, respectively (P = 0.11 for inter-
action). Across myelofibrosis subtypes (primary 
myelofibrosis, post–polycythemia vera myelofibro-
sis, and post–essential thrombocythemia myelo-
fibrosis), patients who received ruxolitinib had a 
decrease in spleen volume and improvement in the 
total symptom score; patients receiving placebo 
had increases in spleen volume (P = 0.52 for inter-
action) and worsening of the total symptom score 
(P = 0.46 for interaction) (Fig. S5A and S5B in the 
Supplementary Appendix).
Biomarkers
In a prespecified analysis of biomarkers, patients 
who received ruxolitinib had mean reductions in 
the JAK2 V617F allele burden of 10.9% at week 24 
and 21.5% at week 48; patients who received pla-
cebo had a mean increase of 3.5% at week 24 and 
6.3% at week 48 (Fig. S6 in the Supplementary 
Appendix). Furthermore, patients receiving ruxoli-
tinib had reductions in plasma levels of C-reactive 
protein and the proinflammatory cytokines tumor 
necrosis factor α and interleukin-6, and they had 
increases in levels of plasma leptin and erythro-






























































































































Figure 1. Change in Spleen Volume.
Panel A shows the results of the intention-to-treat anal-
ysis of the percentage of patients in each study group 
who reached the primary end point of a reduction of 
35% or more in spleen volume as assessed by means 
of magnetic resonance imaging (MRI) or computed  
tomography (CT). Patients who discontinued the study 
drug before week 24 or crossed over before week 24 were 
counted as not having had a response. Only patients 
with baseline data were included in this analysis. I bars 
denote 95% confidence intervals. CI denotes confidence 
interval. Panel B shows the percent change from base-
line in spleen volume at week 24 (in 139 patients in the 
ruxolitinib group and 106 in the placebo group) or at 
the last evaluation before week 24 (in 16 patients in the 
ruxolitinib group and 47 in the placebo group). Data for 
1 patient with a missing baseline value are not included 
on the graph. Most patients in the ruxolitinib group 
(150 of 155) had a reduction in spleen volume, where-
as most patients in the placebo group had either an in-
crease in spleen volume (102 of 153 patients) or no change 
(15 of 153 patients). Panel C shows the median percent 
change in spleen volume as assessed by means of MRI 
or CT over time. Reductions in spleen volume were ap-
parent at the first on-study measurement at 12 weeks 
and were maintained over the course of the study. The 
upper edge of each I bar corresponds to the 75th per-
centile, and the lower edge to the 25th percentile.
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Overall Survival
For the secondary end point of overall survival, at 
the time of data cutoff, 10 deaths were reported 
in the ruxolitinib group (6.5%) as compared with 
14 deaths in the placebo group (9.1%) (hazard ratio, 
0.67; 95% CI, 0.30 to 1.50; P = 0.33). Subsequently, a 
survival analysis based on a planned data cutoff 
with 4 additional months of follow-up (median 
follow-up, 51 weeks) revealed a significant survival 
advantage for patients who received ruxolitinib, 
with 13 deaths in the ruxolitinib group (8.4%) and 
24 deaths in the placebo group (15.6%) (hazard 
ratio, 0.50; 95% CI, 0.25 to 0.98; P = 0.04) (Fig. 3).
Safety
A total of 155 patients in the ruxolitinib group and 
151 in the placebo group received at least one 
dose of the study medication and were included 
in the analysis of safety. The number of patient-
years of exposure was 105 in the ruxolitinib group 
and 87 in the placebo group; study discontinuation 
and crossover to ruxolitinib accounted for lower 
exposure in the placebo group. Seventeen patients 
who received ruxolitinib (11.0%) and 16 patients 
who received placebo (10.6%) discontinued the 
study treatment because of adverse events (of any 
grade). Twenty deaths occurred during the study or 
within 28 days after the last dose was administered 
(9 deaths in the ruxolitinib group and 11 deaths in 
the placebo group, including 1 death after cross-



































































































































































































Figure 2. Change in Symptom Scores.
Panel A shows the results of an intention-to-treat analysis 
of the proportion of patients with at least a 50% reduction 
in the total symptom score over time (each value plotted 
represents the moving average for the previous 7 days). 
Patients who discontinued the study drug or for whom 
data were missing were considered not to have had a re-
sponse. The majority of responses occurred rapidly, with-
in the first 4 weeks after treatment. Only patients with 
baseline data were included in this analysis. Panel B 
shows the percent change from baseline in the total 
symptom score at week 24 (in 129 patients in the ruxoli-
tinib group and 103 patients in the placebo group) and  
at the last evaluation during receipt of the randomly as-
signed study drug (in 16 patients in the ruxolitinib group 
and 42 patients in the placebo group). Five patients with 
a baseline score of 0, 8 patients with missing baseline val-
ues, and 6 patients with insufficient data after baseline 
are not included. Whereas most patients who received 
ruxolitinib had a reduction in the total symptom score, 
the majority of patients who received placebo had a wors-
ening of symptoms (worsening in the total symptom 
score of ≥150% is shown as 150%). Panel C shows the 
mean percent change in the score for each symptom in 
the modified Myelofibrosis Symptom Assessment Form, 
version 2.0. All symptoms improved in the ruxolitinib 
group and worsened in the placebo group (P<0.01 for all 
comparisons with placebo). T bars denote standard errors.
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detailed information). Principal causes of death in 
the ruxolitinib group were muscle weakness and 
general deterioration, subdural hematoma, renal 
failure, non–small-cell lung cancer, acute myeloid 
leukemia (AML), pneumonia (in 2 patients), and 
sepsis (in 2 patients). Principal causes of death in 
the placebo group were staphylococcal infection, 
gastrointestinal hemorrhage, intestinal perfora-
tion, multiorgan failure, pneumonia, sepsis (in 
2 patients), and disease progression (in 4 patients).
Overall, nonhematologic adverse events oc-
curred at a similar rate in the two groups. Events 
that occurred more frequently in the ruxolitinib 
group were ecchymosis, dizziness, and headache 
(predominantly grade 1 or 2) (Table 2). The most 
common grade 3 or 4 nonhematologic adverse 
events (abdominal pain, fatigue, and dyspnea) oc-
curred more frequently in the placebo group.
Anemia and thrombocytopenia were the most 
frequent hematologic adverse events (overall and 
grade 3 or 4 events) (Table 2) and a reason for 
treatment discontinuation in one patient in each 
study-drug group for each event. About half of all 
grade 3 or 4 adverse events of anemia in the rux-
olitinib group occurred during the first 8 weeks 
of therapy. The mean hemoglobin level in patients 
who received ruxolitinib reached a nadir of 95 g 
per liter after approximately 8 to 12 weeks of 
therapy (Fig. S8 in the Supplementary Appendix), 
with an increase by week 24 to a new steady state 
(101 g per liter). The monthly prevalence of grade 
3 or 4 anemia and the proportion of patients re-
quiring transfusions (1 or more units of red cells) 
also followed a pattern that was consistent with 
changes in the hemoglobin level over time (Fig. 
S9A and S9B in the Supplementary Appendix). Ac-
cording to the response criteria of the Interna-
tional Working Group for Myelofibrosis Research 
and Treatment, 41.2% of patients in the ruxolitinib 
group and 46.9% of patients in the placebo group 
who were dependent on transfusions at baseline 
were classified as transfusion-independent during 
the study (Table S4 in the Supplementary Appen-
dix). In the ruxolitinib group, patients with new-
onset grade 3 or 4 anemia had improvements in 
symptoms and reductions in spleen volume that 
were similar to those in patients without anemia 
(Fig. 9C and 9D in the Supplementary Appendix).
Approximately half the grade 3 or 4 thrombo-
cytopenia events (11 of 20) occurred during the 
first 8 weeks of treatment (Fig. S10 in the Supple-
mentary Appendix) and led to dose adjustments or 
brief treatment interruptions. Five patients had 
more than one episode of grade 3 or 4 thrombo-
cytopenia. Grade 3 episodes of bleeding (terms for 
bleeding events are described in the Supplementary 
Appendix) occurred in 2.6% of patients who re-
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Figure 3. Overall Survival.
Kaplan–Meier estimates of overall survival, including 4 months of additional follow-up after the primary analysis, 
are shown. There were 13 deaths in the ruxolitinib group (8.4%) and 24 deaths in the placebo group (15.6%) during 
a median follow-up period of 51 weeks. Tick marks indicate censoring times for individual patients.
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received placebo. Grade 4 episodes of bleeding 
occurred in 1.3% of patients who received ruxoli-
tinib and in 1.3% of patients who received place-
bo. Bruising (bleeding events related to skin and 
subcutaneous tissue) (see the Supplementary Ap-
pendix) was assessed separately. A total of 23.2% 
of patients who received ruxolitinib and 14.6% of 
patients who received placebo had bruising; all 
events were grade 1 or 2 except for one grade 
3 event in the ruxolitinib group.
Among patients in whom the study drug was 
interrupted, symptoms (assessed by means of the 
total symptom score) returned to baseline levels 
over a period of approximately 1 week (Fig. S11 in 
the Supplementary Appendix). Adverse events of 
grade 3 or higher developed in 8 of 49 patients in 
the ruxolitinib group (16.3%) and in 7 of 54 pa-
tients in the placebo group (13.0%) after interrup-
tion of the study drug and in 12 of 21 patients in 
the ruxolitinib group (57.1%) and 17 of 37 patients 
in the placebo group (45.9%) after discontinuation. 
There was no clear pattern in these events to sug-
gest a specific withdrawal effect (Tables S5 and S6 
in the Supplementary Appendix).
Two patients in the ruxolitinib group had a 
transformation to AML during the study: one pa-
tient with 7% bone marrow blasts at baseline and 
a history of breast cancer had AML transformation 
after 8 months in the study; the second patient 
entered the study with 2% bone marrow blasts and 
a trisomy 8 chromosomal abnormality at baseline 
and had AML transformation after 5 months in the 
study. There were no transformations in the pla-
cebo group.
Discussion
In this study, ruxolitinib therapy was significantly 
more effective than placebo with respect to all pri-
mary and secondary efficacy end points, as well as 
in an updated analysis of overall survival. In the 
ruxolitinib group, 41.9% of patients met the de-
fined response threshold of a reduction of 35% or 
more in spleen volume, and nearly all the patients 
had some reduction in spleen volume. Reductions 
in spleen volume were durable; 67.0% of patients 
with a response had this response for 48 weeks or 
longer with continued therapy.
Improvements in symptoms were measured 
with the use of the modified MFSAF, version 2.0, 
diary, a tool designed specifically to assess symp-
toms of myelofibrosis. The majority of patients 
had improvements in symptoms, which occurred 
even in patients who did not have a reduction in 
spleen volume of 35% or more. In contrast, most 
patients who received placebo had progressive 
splenomegaly and worsening of myelofibrosis-
related symptoms. Changes in symptoms record-
ed with the MFSAF were directionally consistent 
with the assessments made with other validated 
and common patient-reported outcome instru-
ments used in this study.
Anemia and thrombocytopenia were more 
common in patients who received ruxolitinib than 
in patients who received placebo. These adverse 
events were manageable, as evidenced by the low 
discontinuation rate (one patient in each group for 
each event). Thrombocytopenia rarely recurred at 
a grade 3 or 4 level after appropriate dose modi-
fications and was not associated with an increase 
in bleeding events, although bruising was more 
common in the ruxolitinib group. The prevalence 
of grade 3 or 4 anemia peaked after approximately 
8 to 12 weeks of ruxolitinib therapy, subsequently 
Table 2. Adverse Events Observed in 10% or More of Patients Who Received 
Ruxolitinib.











Fatigue 25.2 5.2 33.8 6.6
Diarrhea 23.2 1.9 21.2 0
Peripheral edema 18.7 0 22.5 1.3
Ecchymosis 18.7 0 9.3 0
Dyspnea 17.4 1.3 17.2 4.0
Dizziness 14.8 0.6 6.6 0
Nausea 14.8 0 19.2 0.7
Headache 14.8 0 5.3 0
Constipation 12.9 0 11.9 0
Vomiting 12.3 0.6 9.9 0.7
Pain in extremity 12.3 1.3 9.9 0
Insomnia 11.6 0 9.9 0
Arthralgia 11.0 1.9 8.6 0.7
Pyrexia 11.0 0.6 7.3 0.7
Abdominal pain 10.3 2.6 41.1 11.3
Hematologic abnormalities*
Anemia 96.1 45.2 86.8 19.2
Thrombocytopenia 69.7 12.9 30.5 1.3
Neutropenia 18.7 7.1 4.0 2.0
* Hematologic abnormalities are based on laboratory values. The data shown 
are for events of the worst grade during the study, regardless of whether this 
grade was a change from the baseline grade.
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decreasing to levels similar to those in patients 
who received placebo. In the ruxolitinib group, 
patients with new-onset grade 3 or 4 anemia had 
symptomatic improvement similar to that in pa-
tients without anemia. In the placebo group, pa-
tients with and those without grade 3 or 4 anemia 
had worsening of symptoms, which was greater in 
patients with anemia.
Transformation to AML occurred in 2 patients 
in this study; both patients received ruxolitinib and 
had baseline characteristics that placed them at 
increased risk for transformation. In a separate 
phase 3 trial with a median follow-up of 61 weeks, 
there were no transformations to AML in 146 pa-
tients who received ruxolitinib and two transforma-
tions in 73 patients who received the best available 
therapy.16 Longer-term follow-up will be required 
to better define rates of AML transformation.
After interruption of ruxolitinib therapy, myelo-
fibrosis-related symptoms gradually returned to 
baseline levels. A between-group comparison of 
adverse events reported after interruption or per-
manent discontinuation of the study drug showed 
no clear pattern of a specific withdrawal effect.
In conclusion, ruxolitinib was associated with 
reductions in splenomegaly and symptoms that are 
prominent manifestations of myelofibrosis and 
appeared to be associated with an improvement 
in overall survival. Toxic effects were generally 
managed with dose modification. These findings 
show that ruxolitinib is an effective therapy for 
myelofibrosis.
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